The Boston Scientific spinal cord stimulator price is not a single public list price. In the United States, the figure that matters is usually the total allowed amount or negotiated rate for an episode of care. That episode may include the trial, leads, implantable pulse generator, facility fee, physician fee, anesthesia, programming and follow-up. Medicare’s 2026 national figures show that insertion or replacement of a spinal neurostimulator pulse generator can carry an average total allowed amount of about $27,803 in an ambulatory surgical center and about $31,844 in a hospital outpatient department. These figures are not a complete implant quote for every patient, and they are not a Boston Scientific retail price. They are useful benchmarks for understanding why estimates vary so widely.
Why there is no single public price for a Boston Scientific SCS
Boston Scientific sells spinal cord stimulation systems through clinical and provider channels, not as consumer products with a standard online retail price. A patient usually does not buy the device directly. Instead, a hospital, ambulatory surgical center or physician practice bills for a set of services and implanted components under procedure, facility and device-related codes.
That is why two people asking about the same Boston Scientific spinal cord stimulator may receive very different estimates. One estimate may describe only the implantable pulse generator. Another may include lead placement, the operating room, anesthesia, imaging, recovery, professional fees and initial programming. A third may show the patient’s coinsurance after insurance adjustments rather than the total allowed amount.
Boston Scientific’s current SCS portfolio includes rechargeable and non-rechargeable implantable pulse generator options, including WaveWriter Alpha and WaveWriter Alpha Prime configurations. Its FDA labeling describes SCS systems as implanted devices that deliver electrical stimulation to the dorsal column of the spinal cord for chronic intractable pain of the trunk and/or limbs. Device features matter clinically, but the patient’s bill is often driven as much by procedure coding, site of service and insurance rules as by brand.
For more coverage of related implant technologies, visit our Spinal Devices section.
2026 Medicare benchmarks for common SCS cost components
Medicare figures are not the same as commercial insurance prices, cash-pay quotes or hospital charges. They are still useful because they provide a transparent reference point and separate common spinal cord stimulation procedures by CPT code and site of service. Boston Scientific’s 2026 reimbursement guide and Medicare’s Procedure Price Lookup both note that actual reimbursement can vary by payer policy, geography, documentation, diagnosis and care setting.
| Cost component | Common code | What it generally represents | 2026 Medicare national benchmark |
|---|---|---|---|
| Percutaneous lead placement | CPT 63650 | Implantation of an epidural neurostimulator electrode array | About $5,031 in an ASC and $6,511 in a hospital outpatient department, before patient-specific insurance adjustments |
| Paddle lead placement | CPT 63655 | Laminectomy for implantation of plate or paddle electrodes | About $14,406 in an ASC and $19,820 in a hospital outpatient department |
| Generator insertion or replacement | CPT 63685 | Creation of a pocket and connection of the electrode array to the pulse generator or receiver | Medicare’s 2026 Procedure Price Lookup lists about $27,803 total in an ASC and $31,844 total in a hospital outpatient department |
| Revision of percutaneous lead array | CPT 63663 | Revision or replacement of percutaneous electrode array when performed | About $5,076 in an ASC and $6,511 in a hospital outpatient department |
| Generator revision or removal | CPT 63688 | Revision or removal of the implanted pulse generator or receiver | About $2,003 in an ASC and $3,572 in a hospital outpatient department |
The generator code alone can look expensive, but a full permanent implant may involve several billed services. A trial that does not proceed to permanent implantation has a different cost pattern from a successful trial followed by a full implant. A revision or battery replacement years later is also a separate cost event.
What usually changes the final patient bill
The first major variable is the stage of therapy. Spinal cord stimulation usually begins with a temporary trial using external equipment and implanted or temporarily placed leads. If the trial provides adequate relief and the patient remains an appropriate surgical candidate, the care team may proceed to permanent implantation. Medicare’s national coverage policy requires demonstration of pain relief with a temporarily implanted electrode before permanent implantation for covered dorsal column stimulation.
The second variable is the type of lead and surgical approach. Percutaneous leads are commonly placed through a needle into the epidural space. Paddle leads generally require a more invasive surgical approach, which is often reflected in higher facility payment benchmarks. The appropriate approach depends on anatomy, diagnosis, prior surgery, physician judgment and other patient-specific factors.
The third variable is site of service. A procedure performed in an ambulatory surgical center may have a different allowed amount from the same procedure performed in a hospital outpatient department. Hospital-based care may be appropriate for some patients because of medical complexity, but it can change the reimbursement structure.
The fourth variable is insurance design. A patient with Medicare plus supplemental coverage may face a different out-of-pocket amount than a patient with Medicare Advantage, employer coverage, a high-deductible plan or no insurance. Deductibles, coinsurance, prior authorization, in-network status and annual out-of-pocket maximums can matter more than the manufacturer name on the device.
The fifth variable is maintenance over time. Follow-up programming, replacement controllers or chargers, imaging restrictions, lead migration, infection, loss of pain relief and generator replacement can all affect total cost of ownership. Boston Scientific patient materials note that rechargeable systems require charging, while non-rechargeable systems avoid routine charging but may eventually require generator replacement when the battery is depleted.
How Boston Scientific device choice fits into price discussions
It is reasonable to ask whether a Boston Scientific system costs more or less than another manufacturer’s spinal cord stimulator. In practice, the answer is rarely simple. Hospitals and surgery centers may negotiate device purchasing terms privately. Insurers may pay by procedure group, site of service and contract rules rather than publishing a brand-by-brand consumer price.
For that reason, patients and purchasing teams should not judge price from the implantable pulse generator alone. Boston Scientific’s WaveWriter Alpha portfolio includes rechargeable and non-rechargeable options, 16-contact and 32-contact configurations, MRI-conditional labeling under specified conditions and multiple therapy programming options. Other manufacturers may offer different waveforms, battery designs, MRI labeling and programmer ecosystems. Those differences can affect clinical selection, workflow and long-term maintenance, but they do not automatically translate into a predictable patient price.
A useful comparison should include three layers: the clinical indication, the complete episode cost and the long-term service implications. If a clinician recommends a Boston Scientific device, the patient can still ask for the planned CPT codes, device-related HCPCS or C-codes where applicable, expected setting, in-network status and estimated out-of-pocket amount before authorizing the procedure. See also: Implants.
Coverage and medical necessity can matter as much as list price
Coverage rules are a major reason spinal cord stimulator pricing can feel confusing. CMS National Coverage Determination 160.7 treats central nervous system stimulators, including dorsal column spinal cord neurostimulation, as potentially covered for chronic intractable pain when conditions are met. Those conditions include use as a late or last resort after other treatment modalities have been tried or judged unsuitable, careful screening and evaluation, appropriate facilities and personnel, and a successful temporary trial before permanent implantation.
Commercial insurers and Medicare Advantage plans may apply their own prior authorization processes. They may request records showing diagnosis, conservative treatment history, psychological screening, trial results and the planned device and procedure codes. A denial, delay or missing documentation can change both timing and patient financial responsibility.
Patients should also distinguish between coverage of the procedure and coverage of related services. A plan may cover the implant but apply separate cost sharing to imaging, anesthesia, facility fees, postoperative visits, programming, medications or treatment of complications. Before a trial, patients should ask whether the trial and permanent implant require separate authorizations.
Reading value beyond the upfront price
Upfront cost is only one part of the spinal cord stimulation value question. Some economic reviews have concluded that SCS can become cost-effective for selected chronic pain indications if durable pain relief reduces other healthcare use. Results vary by diagnosis, comparator, study design, device generation and follow-up period.
A large JAMA Neurology analysis published in 2022 reported that, in a real-world matched comparison, SCS was associated with substantially higher first-year healthcare costs than conventional medical management, while second-year costs were similar. The same study reported SCS-related complications in 17.9% of treated patients within two years and revisions or removals in 22.1%. Those findings were not specific to Boston Scientific devices and should not be read as a brand comparison, but they show why revisions, removals and loss of effectiveness belong in any serious cost discussion.
The practical conclusion is balanced: a lower upfront estimate is not automatically better if it omits likely follow-up needs, and a higher estimate is not automatically worse if it reflects the appropriate care setting for a medically complex patient. The best financial review pairs the clinical plan with an itemized estimate and a realistic discussion of what happens if the trial fails, the implant needs revision or pain relief declines over time.
Questions to ask before accepting an estimate
- Is this estimate for the trial, the permanent implant or both? The trial and permanent implant are usually separate episodes with separate billing.
- Which CPT codes are expected? Ask whether the plan includes percutaneous leads, paddle leads, generator insertion, programming or other procedures.
- Which facility will bill the procedure? The same procedure may price differently in an ASC and a hospital outpatient department.
- Is the physician, facility, anesthesiology group and device-related care in network? Out-of-network components can change the patient bill significantly.
- What happens financially if the trial is unsuccessful? A failed trial may still generate facility and professional charges.
- What future costs should be expected? Ask about programming visits, generator replacement, charger or controller replacement, imaging requirements and revision procedures.
- Does the estimate include the Boston Scientific representative’s role? Manufacturer representatives may support programming and device education, but physician billing rules depend on payer requirements and who performs the billable service.
Frequently asked questions
What is the average Boston Scientific spinal cord stimulator price?
There is no single public average device price that applies to every patient. Publicly available U.S. benchmarks are usually procedure-level figures. In 2026 Medicare data, generator insertion or replacement under CPT 63685 is listed around $27,803 total in an ASC and $31,844 total in a hospital outpatient department. A complete SCS episode may include additional trial, lead placement, anesthesia, programming and follow-up costs.
Does insurance usually cover a Boston Scientific spinal cord stimulator?
Coverage may be available when medical necessity criteria are met, but authorization requirements vary. Medicare’s national policy covers certain dorsal column spinal cord stimulation for chronic intractable pain when specific conditions are satisfied, including a successful temporary trial before permanent implantation. Private insurers may require their own documentation and prior authorization.
Is the trial included in the permanent implant price?
Often it is not included as one simple package. The trial is typically billed separately from the permanent implant. Patients should ask for separate estimates for the trial, the permanent implant and any likely follow-up programming or revision services.
Do rechargeable and non-rechargeable Boston Scientific systems cost the same?
Not necessarily. Pricing can depend on provider purchasing arrangements, payer contracts, device configuration and procedure coding. A rechargeable system may involve charging equipment and patient charging routines, while a non-rechargeable system avoids recharging but may require generator replacement when the battery reaches end of service.
Why is my hospital estimate higher than Medicare’s published amount?
Hospital charge masters, commercial negotiated rates, out-of-network billing, bundled services, anesthesia, imaging, medical complexity and local market contracts can all produce estimates that differ from Medicare national averages. Medicare figures are benchmarks, not universal retail prices.
Source note: The pricing and coverage discussion above is based on publicly available 2026 Medicare procedure benchmarks, CMS National Coverage Determination 160.7, Boston Scientific spinal cord stimulation reimbursement materials and product labeling, and peer-reviewed cost and outcomes literature. It is intended for industry education and should not replace a patient-specific estimate from a provider or insurer.